Summary:
20 week double blind study followed by a 52 week open label extension, to evaluate the safety and efficacy of a potential new treatment in patients with pain associated with trigeminal neuralgia.
Qualified Participants Must:
• Be 18-75 years old
•
Be diagnosed with trigeminal neuralgia and have pain
•
Be willing to discontinue current pain medications
Qualified Participants May Receive:
study related care at no cost
compensation for time and travel